6533b831fe1ef96bd1299762
RESEARCH PRODUCT
P-34 The randomized, double-blind, placebo-controlled phase 3 trial KEYNOTE-975: Pembrolizumab vs placebo in patients with esophageal carcinoma receiving concurrent definitive chemoradiotherapy
Antoine AdenisHarvey J. MamonKyoko KatoToshihiko DoiC. ShihJaafar BennounaByoung Chul ChoPeter C. EnzingerMarkus MoehlerLiang ShenManish A. ShahXiaolong FuAnjali DesaiPooja Bhagiasubject
medicine.medical_specialtybusiness.industryHematologyDefinitive chemoradiotherapyPembrolizumabPlacebomedicine.diseaseGastroenterologyDouble blindOncologyInternal medicineCarcinomaMedicineIn patientbusinessyear | journal | country | edition | language |
---|---|---|---|---|
2020-07-01 | Annals of Oncology |